[Deferasirox--a new oral iron chelator--review]

Area of Science:

• Pharmacology
• Hematology
• Drug Development

Background:

• Deferasirox is an oral iron chelator approved for transfusion-dependent patients with severe chronic iron overload.
• It is recommended for beta-thalassemia patients over six years old.
• Clinical studies are ongoing in China to further evaluate deferasirox.

Purpose of the Study:

• To review existing studies and recent advancements concerning deferasirox.
• To assess the safety and efficacy of deferasirox in managing chronic iron overload.
• To highlight potential rare adverse events and novel therapeutic properties of deferasirox.

Main Methods:

• Review of Phase II and III clinical trials and pharmacokinetic data.
• Analysis of studies on deferasirox's efficacy in reducing myocardial and hepatic iron load.
• Examination of reported adverse events and patient acceptance.

Main Results:

• Deferasirox is a safe and effective oral iron chelator, significantly decreasing iron load in the heart and liver.
• Common side effects include gastrointestinal symptoms and rash; rare adverse events necessitate careful monitoring.
• The drug is also indicated for patients post-auto-SCT and those with Fanconi syndrome-related renal issues.

Conclusions:

• Deferasirox is a valuable therapeutic option for chronic iron overload, but dosage adjustment based on individual patient parameters is crucial, as serum ferritin alone is not a reliable monitoring index.
• Clinicians must be aware of rare adverse events, especially in specific patient populations.
• Emerging evidence suggests deferasirox may possess additional properties, including anti-fungal and anti-cell proliferation activities.